Literature DB >> 24472052

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013.

Daisuke Aoki1.   

Abstract

We present the Patient Annual Report in 2011 and the Treatment Annual Report in 2005 that were collected and analyzed by the Japan Society of Obstetrics and Gynecology. Data on 15,698 patients with cervical cancer, 7713 with endometrial cancer and 4672 with ovarian cancer in whom treatment was started in 2011 and data on the prognosis of 2985 patients with cervical cancer, 2812 with endometrial cancer, and 1839 with ovarian cancer who were started on treatment in 2005 were analyzed and summarized. Patient Annual Report in 2011: Stage 0 accounted for 58%, stage I for 24%, stage II for 9%, stage III for 5%, and stage IV for 4% of all the patients with cervical cancer. Stage 0 accounted for 6%, stage I for 61%, stage II for 8%, stage III for 18%, and stage IV for 7% of patients with endometrial cancer. Stage I accounted for 43%, stage II for 9%, stage III for 29%, and stage IV for 8% of patients with ovarian cancer. Treatment Annual Report in 2005: The 5-year overall survival rates of patients with cervical cancer were 91% in stage I, 78% in stage II, 57% in stage III, and 30% in stage IV. The 5-year overall survival rates of patients with endometrial cancer were 95% in stage I, 89% in stage II, 77% in stage III, and 23% in stage IV. The 5-year overall survival rates of patients with ovarian surface epithelial-stromal tumors were 92% in stage I, 75% in stage II, 50% in stage III and 39% in stage IV.
© 2014 The Author. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  Japan; annual report; cervical cancer; endometrial cancer; gynecological cancer; ovarian cancer

Mesh:

Year:  2014        PMID: 24472052     DOI: 10.1111/jog.12360

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  15 in total

1.  How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.

Authors:  Yoshihito Yokoyama; Kiyoshi Ito; Kiyoshi Takamatsu; Kazuhiro Takehara; Toru Nakanishi; Kenichi Harano; Hidemichi Watari; Nobuyuki Susumu; Daisuke Aoki; Toshiaki Saito
Journal:  Int J Clin Oncol       Date:  2015-03-06       Impact factor: 3.402

Review 2.  Adenocarcinoma of the uterine cervix: why is it different?

Authors:  Keiichi Fujiwara; Bradley Monk; Mojgan Devouassoux-Shisheboran
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

3.  Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer.

Authors:  Takuro Yamamoto; Taisuke Mori; Morio Sawada; Hiroshi Matsushima; Fumitake Ito; Makoto Akiyama; Jo Kitawaki
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

4.  Resection of the vaginal vault for vaginal recurrence of cervical cancer after hysterectomy and brachytherapy.

Authors:  Akiko Abe; Maki Matoda; Sanshiro Okamoto; Eiji Kondo; Kazuyoshi Kato; Kohei Omatsu; Kenji Umayahara; Kuniko Utsugi; Nobuhiro Takeshima
Journal:  World J Surg Oncol       Date:  2015-04-02       Impact factor: 2.754

5.  The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker.

Authors:  Shuo Chen; Kai-Xuan Sun; Bo-Liang Liu; Zhi-Hong Zong; Yang Zhao
Journal:  Oncotarget       Date:  2016-05-10

6.  Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.

Authors:  Kaoru Yamawaki; Tatsuya Ishiguro; Yutaro Mori; Kosuke Yoshihara; Kazuaki Suda; Ryo Tamura; Masayuki Yamaguchi; Masayuki Sekine; Katsunori Kashima; Masaya Higuchi; Masahiro Fujii; Koji Okamoto; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2017-04-19       Impact factor: 6.716

Review 7.  Clinical statistics of gynecologic cancers in Japan.

Authors:  Wataru Yamagami; Satoru Nagase; Fumiaki Takahashi; Kazuhiko Ino; Toru Hachisuga; Daisuke Aoki; Hidetaka Katabuchi
Journal:  J Gynecol Oncol       Date:  2017-02-10       Impact factor: 4.401

8.  Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.

Authors:  Michael L Friedlander; Kenneth Russell; Sherri Millis; Zoran Gatalica; Ryan Bender; Andreas Voss
Journal:  Int J Gynecol Cancer       Date:  2016-05       Impact factor: 3.437

9.  Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.

Authors:  Osamu Inoue; Toshio Hamatani; Nobuyuki Susumu; Wataru Yamagami; Seiji Ogawa; Takashi Takemoto; Akira Hirasawa; Kouji Banno; Naoaki Kuji; Mamoru Tanaka; Daisuke Aoki
Journal:  Reprod Biol Endocrinol       Date:  2016-01-15       Impact factor: 5.211

10.  Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.

Authors:  Toshio Nishimura; Kazuto Nakamura; Soichi Yamashita; Sadatomo Ikeda; Keiko Kigure; Takashi Minegishi
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.